Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Genetics & Genomic Medicine"
DOI: 10.1002/mgg3.809
Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of BCR‐ABL fusion gene (GenBank accession NC_000022.11). In the vast majority of CML patients, the typical subtype of BCR‐ABL transcript are b3a2, b2a2… read more here.
Keywords: bcr abl; myeloid leukemia; abl transcript; chronic myeloid ... See more keywords
New Pharmacophore Fingerprints and Weight‐matrix Learning for Virtual Screening. Application to Bcr‐Abl Data
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Informatics"
DOI: 10.1002/minf.202200210
Abstract: In this work, we propose to analyze the potential of a new type of pharmacophoric descriptors coupled to a novel feature transformation technique, called Weight‐Matrix Learning (WML, based on a feed‐forward neural network). The application… read more here.
Keywords: weight matrix; application; virtual screening; bcr abl ... See more keywords
Synthesis and biological evaluation of phenyl-amino-pyrimidine and indole/oxindole conjugates as potential BCR-ABL inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Medicinal Chemistry Research"
DOI: 10.1007/s00044-019-02318-4
Abstract: AbstractIndole/isatin conjugated phenyl-amino-pyrimidine derivatives have been synthesized, characterized and evaluated in vitro for their potential as BCR-ABL inhibitors. Among the series, all derivatives (7a–7o) were found to be more cytotoxic than standard Imatinib against K-562… read more here.
Keywords: bcr; abl inhibitors; amino pyrimidine; bcr abl ... See more keywords
Lab tests for MPN.
Sign Up to like & getrecommendations! Published in 2022 at "International review of cell and molecular biology"
DOI: 10.1016/bs.ircmb.2021.02.010
Abstract: Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of… read more here.
Keywords: biology; calr; bcr abl; test ... See more keywords
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Sign Up to like & getrecommendations! Published in 2019 at "Cellular signalling"
DOI: 10.1016/j.cellsig.2019.109360
Abstract: Epigenetic disorders play a key role in tumorigenesis and development, among which histone methylation abnormalities are common. While patients living with chronic myeloid leukemia in the chronic phase (CML-CP) have a good response to TKI,… read more here.
Keywords: blast crisis; rbp2; bcr abl; expression ... See more keywords
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2020.112710
Abstract: Breakpoint cluster region-Abelson (Bcr-Abl) kinase is a key driver in the pathophysiology of chronic myelogenous leukemia (CML). Broadening the chemical diversity of Bcr-Abl kinase inhibitors with novel chemical entities possessing favorable target potency and cellular… read more here.
Keywords: target; bcr abl; activity; abl kinase ... See more keywords
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Sign Up to like & getrecommendations! Published in 2021 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2021.173944
Abstract: As the critical driving force for chronic myeloid leukemia (CML), BCR gene fused ABL kinase has been extensively explored as a validated target of drug discovery. Although imatinib has achieved tremendous success as the first-line… read more here.
Keywords: cml; kinase; bcr abl; imatinib ... See more keywords
siRNA‐cell‐penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2016.11.027
Abstract: &NA; Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by a single gene mutation, a reciprocal translocation that originates the Bcr‐Abl gene with constitutive tyrosine kinase activity. As a monogenic disease, it is an… read more here.
Keywords: bcr abl; bv173 cell; cell; sirna ... See more keywords
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.04.001
Abstract: Fast identification of BCR-ABL fusion genes is critical for precise diagnosis, risk stratification and therapy scheme selection in leukemia. More convenient methods are needed for quickly detection of the BCR-ABL fusion genes. Multiplex fluorescent reverse… read more here.
Keywords: fusion genes; bcr; abl fusion; bcr abl ... See more keywords
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
Sign Up to like & getrecommendations! Published in 2021 at "Experimental cell research"
DOI: 10.1016/j.yexcr.2021.112708
Abstract: The resistance to tyrosine kinase inhibitors is currently a major problem for chronic myeloid leukemia (CML) treatment and HSPA8 is highly expressed and a hallmark of poor prognosis in several human cancers. However, its role… read more here.
Keywords: cml; cml cells; proliferation; bcr abl ... See more keywords
Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c00082
Abstract: BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most… read more here.
Keywords: bcr; abl kinase; bcr abl; t315i ... See more keywords